NEW YORK, May 21 (Reuters) - Cigna CI.N said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more than $200 a month out-of-pocket for weight-loss drugs Wegovy and Zepbound.
Cigna's pricing compares to the cash-pay market for weight-loss drugs, said Harold Carter, a senior vice president at Evernorth.
(Reporting by Amina Niasse; editing by Caroline Humer)
((amina.niasse@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.